Developing new drugs to treat resistant prostate cancer
Official title: Targeting chemoresistant prostate cancer with novel EED inhibitors
Funded at Clark Atlanta University · NIH-11191486 · Data updated 2026-11-12
This study is looking for new ways to help men with advanced prostate cancer who aren't responding to the usual chemotherapy by testing new compounds that might make the treatment work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clark Atlanta University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $428,304 |
| NIH project number | 5R01CA256058-04 |
| Project ID | NIH-11191486 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer who have developed resistance to standard chemotherapy.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not undergone chemotherapy may not benefit from this research.
What this research studies
This research focuses on overcoming resistance to docetaxel, the standard chemotherapy for advanced prostate cancer, which often becomes ineffective. The team will design and test new chemical compounds that inhibit a specific protein interaction believed to help cancer cells survive treatment. They will evaluate these compounds in laboratory models to determine their effectiveness and safety. The goal is to identify promising candidates that could lead to new therapies for patients with chemoresistant prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer who currently have limited effective therapies.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
Clark Atlanta University
Atlanta, United States Active
Researchers
- Principal investigator: Wu, Daqing — Clark Atlanta University
- Study coordinator: Wu, Daqing
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.